Immunomodulation of cancer: potential use of selectively replicating agents

Agha-Mohammadi, Siamak; Lotze, Michael T.

doi:10.1172/jci10026

Cited by 41 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inherent ability of replication-competent adenoviruses to sensitize tumor cells to chemotherapy was a novel discovery that has led to chemosensitization strategies. These data will support the further development of adenoviral agents, including second-generation constructs containing exogenous therapeutic genes to enhance both local and systemic antitumoral activity Hermiston, 2000;Agha-Mohammadi and Lotze, 2000). In addition to adenovirus, other viral species are being developed including herpesvirus, vaccinia, reovirus and measles virus (Kirn, 2000a;Martuza, 2000;Norman and Lee, 2000;Mastrangelo et al, 2000;Co ey et al, 1998;Martuza et al, 1991;Kirn, 2000b;Lattime et al, 1996).…”

Section: Discussionmentioning

confidence: 93%

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

Kirn

2000

Oncogene

127

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

Kirn

2000

Oncogene

127

View full text Add to dashboard Cite

“…23,24 Other areas that hold potential value would be the inclusion of cytokines such as GM-CSF or IL-2, or anti-angiogenesis genes (endostatin or angiostatin) that might augment antitumor responses. 29 One important factor to keep in mind, however, is that although the potential efficacy of these viruses can be tested in existing mouse models, testing the safety of any replicating adenoviral vector will continue to be difficult since commonly used laboratory animals do not allow replication of the virus. 11,25 In summary, a replicating adenoviral vector containing the HSVtk transgene appears to have efficacy against flank and intraperitoneal tumors.…”

Section: Discussionmentioning

confidence: 99%

Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy

et al. 2001

View full text Add to dashboard Cite

Replication-incompetent adenoviruses (Ad) carrying the herpes simplex thymidine kinase (HSVtk) gene have been used in a number of human cancer gene therapy trials, however transduction has generally been limited to a small minority of tumor cells. To solve this problem, replication-competent adenoviral vectors carrying transgenes such as HSVtk have been developed. However, contradictory evidence exists regarding the efficacy of these new vectors. Accordingly, we constructed and tested a replication-competent E3-deleted adenoviral vector containing the HSVtk suicide gene driven by the endogenous E3 promoter (Ad.wt.tk). This virus

show abstract

“…1 The immune response also can be modulated by genetic adjuvants using vectors expressing biologically active cytokines. 2 DNA-based therapy and immunization have primarily been performed using either intradermal or intramuscular routes. Skeletal muscle can principally express a foreign gene intramuscularly administered by needle syringe injection, 3 making it a potential target tissue for somatic gene therapy of muscle and nonmuscle diseases.…”

mentioning

confidence: 99%

Long-lasting gene expression by particle-mediated intramuscular transfection modified with bupivacaine: combinatorial gene therapy with IL-12 and IL-18 cDNA against rat sarcoma at a distant site

et al. 2003

View full text Add to dashboard Cite

The immune response is modulated by genetic adjuvants using plasmid vectors expressing cytokines. Skeletal muscle can express a foreign gene intramuscularly administered via a needle injection, and the potential of muscle as a target tissue for somatic gene therapy in treating cancer has been explored. In the present study, we investigated the efficacy of particle-mediated intramuscular transfection modified with a local anesthetic agent, bupivacaine, on luciferase and green fluorescent protein. The results indicate that these proteins are more efficiently expressed and persist longer in muscle modified in this way compared with the needleinjection method. Using an established rat sarcoma model, particle-mediated intramuscular gene-gun therapy with a combination of IL-12 and IL-18 cDNA was conducted. Growth of the distant sarcoma was significantly inhibited by particle-mediated intramuscular combination gene therapy, and the survival rate was also improved. Furthermore, the combination gene-gun therapy maintained significant levels of interferon-g and induced a high activity of tumor-specific cytotoxic T lymphocytes. These results suggest that the sustained local delivery of IL-12 and IL-18 cDNA using intramuscular gene-gun therapy modified with bupivacaine can induce long-term antitumor immunity, and can provide the great advantage of inhibiting the disseminated tumor.

show abstract

Immunomodulation of cancer: potential use of selectively replicating agents

Cited by 41 publications

References 30 publications

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy

Long-lasting gene expression by particle-mediated intramuscular transfection modified with bupivacaine: combinatorial gene therapy with IL-12 and IL-18 cDNA against rat sarcoma at a distant site

Contact Info

Product

Resources

About